Pyxis Oncology’s (PYXS) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report sent to investors on Tuesday,Benzinga reports. HC Wainwright currently has a $5.00 price target on the stock.

Pyxis Oncology Price Performance

Shares of Pyxis Oncology stock opened at $1.20 on Tuesday. The business has a 50-day moving average of $1.16 and a 200 day moving average of $1.15. Pyxis Oncology has a 12 month low of $0.8332 and a 12 month high of $5.3899. The stock has a market capitalization of $74.34 million, a price-to-earnings ratio of -0.75 and a beta of 1.13.

Pyxis Oncology (NASDAQ:PYXS) last announced its earnings results on Thursday, August 14th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. Equities research analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

Several hedge funds and other institutional investors have recently made changes to their positions in PYXS. Renaissance Technologies LLC boosted its stake in shares of Pyxis Oncology by 83.0% in the 4th quarter. Renaissance Technologies LLC now owns 293,354 shares of the company’s stock valued at $458,000 after buying an additional 133,018 shares during the period. Barclays PLC boosted its stake in shares of Pyxis Oncology by 20.2% in the 4th quarter. Barclays PLC now owns 77,013 shares of the company’s stock valued at $121,000 after buying an additional 12,924 shares during the period. Marshall Wace LLP boosted its stake in shares of Pyxis Oncology by 35.7% in the 4th quarter. Marshall Wace LLP now owns 157,953 shares of the company’s stock valued at $246,000 after buying an additional 41,594 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Pyxis Oncology by 35.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 111,051 shares of the company’s stock valued at $173,000 after buying an additional 29,105 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Pyxis Oncology by 36.6% in the 4th quarter. Jane Street Group LLC now owns 67,686 shares of the company’s stock valued at $106,000 after buying an additional 18,128 shares during the period. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.